Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "deficiency"

100 News Found

Thermo Fisher Scientific launches real-time PCR kits for detection of infectious diseases in India
Medical Device | February 15, 2023

Thermo Fisher Scientific launches real-time PCR kits for detection of infectious diseases in India

The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care


Artificial intelligence facilitates low-cost drug repurposing, says GlobalData
Digitisation | February 11, 2023

Artificial intelligence facilitates low-cost drug repurposing, says GlobalData

The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.


Need a paradigm shift for popularising ayurveda in India
News | February 07, 2023

Need a paradigm shift for popularising ayurveda in India

For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions


Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe
Biotech | January 05, 2023

Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency


‘SMART’ program for Ayurveda professionals to boost research in Ayurveda
Policy | January 03, 2023

‘SMART’ program for Ayurveda professionals to boost research in Ayurveda

The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research


Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients
News | October 19, 2022

Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients

MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae


Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
Drug Approval | September 23, 2022

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor


BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
Drug Approval | September 22, 2022

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.


Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection
Drug Approval | September 16, 2022

Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection

The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.


Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal
News | September 10, 2022

Zydus Lifesciences acquires rights to market MonoFerric injections in India and Nepal

MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions